[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587473":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":61,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"The General Authority for Teaching Hospitals and Institutes","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Progesterone group","EXPERIMENTAL","Women will receive low dose progesterone 5 mg intramuscularly as a study group.",[13],"Drug: Progesterone",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Women will receive placebo as a control group",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Progesterone","Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg\u002Fday will be given from cycle day 3 onwards for only 5 days).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Women will receive placebo as a control group. (Placebo 2.5 mg\u002Fday will be given from cycle day 3 onwards for only 5 days).",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Abeer A El Shabasi, MD","CONTACT","00201223331182","abear.elshabacy@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Teaching Hospitals and Institutes","RECRUITING","Cairo","Egypt","EG",{"type":45,"coordinates":46},"Point",[47,48],31.24967,30.06263,{"lat":48,"lon":47},[51,52,55,57,59],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":53,"role":54,"phone":26,"phoneExt":26,"email":26},"Mohamed A Raslan, MD","PRINCIPAL_INVESTIGATOR",{"name":56,"role":54,"phone":26,"phoneExt":26,"email":26},"Mona A Baghdadi, MD",{"name":58,"role":54,"phone":26,"phoneExt":26,"email":26},"Sayida I El-Dessouki, MD",{"name":60,"role":54,"phone":26,"phoneExt":26,"email":26},"Eslam M El-Sayed, MD",{"type":54,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Abeer Ali Elshabacy","Assistant Scientific Consultant Obstetrics and Gynecology Benha Teaching Hospital","100587473","role-of-low-dose-injectable-progesterone-in-triggering-ovulation-100587473",false,"NCT06928844","Role of Low Dose Injectable Progesterone in Triggering Ovulation","Role of Low Dose Injectable Progesterone in Triggering Ovulation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 20 to 35 years.\n* Infertile women.\n* Basal follicle-stimulating hormone (FSH) level \\\u003C10 mIU\u002Fml.\n\nExclusion Criteria:\n\n* Poor ovarian reserve.\n* Immunological disease.\n* Endometriosis.\n* Uterine abnormality.\n* Body mass index (BMI) \\>30 kg\u002Fm2.\n* Endometrial thickness \\\u003C8 or \\>12 mm on the day of triggering.","FEMALE","20 Years","35 Years",{"count":75,"type":76},120,"ESTIMATED","INTERVENTIONAL",[79],"NA","The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.",[82,23,83],"Low Dose","Triggering Ovulation","2025-04-15",{"date":86,"type":87},"2025-04-16","ACTUAL",{"date":84,"type":87},{"date":90,"type":76},"2025-08-01",{"name":5,"class":6},1]